TLR2 and metabolic dysfunction-associated steatohepatitis: Although most of the available studies focus on the role of TLR4 in NASH and atherosclerosis, it has also been shown that TLR2 deficiency in Ldlr−/− mice leads to a reduction in atherogenesis, while administration of TLR2 agonists results in increased atherosclerosis in mice (101).